Journal of Gastric Cancer

The Korean Gastric Cancer Association (대한위암학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical Practice Guidelines for Gastric Cancer in Korea: An Evidence-Based Approach

  • Lee, Jun Haeng (Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Kim, Jae G. (Department of Medicine, Chung-Ang University College of Medicine) ;
  • Jung, Hye-Kyung (Department of Internal Medicine, Ewha Medical Research Institute, Ewha Womans University School of Medicine) ;
  • Kim, Jung Hoon (Department of Radiology and Institute of Radiation Medicine, Seoul National University, College of Medicine) ;
  • Jeong, Woo Kyoung (Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Jeon, Tae Joo (Department of Nuclear Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine) ;
  • Kim, Joon Mee (Department of Pathology, Inha University School of Medicine) ;
  • Kim, Young Il (Department of Surgery, Ewha Womans University School of Medicine) ;
  • Ryu, Keun Won (Center for Gastric Cancer, National Cancer Center) ;
  • Kong, Seong-Ho (Department of Surgery, Seoul National University Hospital) ;
  • Kim, Hyoung-Il (Department of Surgery, Yonsei University College of Medicine) ;
  • Jung, Hwoon-Yong (Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Yong Sik (Department of Internal Medicine, Korea University College of Medicine) ;
  • Zang, Dae Young (Department of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine) ;
  • Cho, Jae Yong (Department of Medical Oncology, Yonsei University College of Medicine) ;
  • Park, Joon Oh (Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Lim, Do Hoon (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Jung, Eun Sun (Department of Pathology, The Catholic University of Korea, Seoul St. Mary's Hospital) ;
  • Ahn, Hyeong Sik (Department of Preventive Medicine, Korea University College of Medicine) ;
  • Kim, Hyun Jung (Department of Preventive Medicine, Korea University College of Medicine)
  • Received : 2014.06.26
  • Accepted : 2014.06.26
  • Published : 2014.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Although gastric cancer is quite common in Korea, the treatment outcome is relatively favorable compared to those in western countries. However, there are currently no Korean multidisciplinary guidelines for gastric cancer. Experts from related societies developed guidelines de novo to meet Korean circumstances and requirements, including 23 recommendation statements for diagnosis (n=9) and treatment (n=14) based on relevant key questions. The quality of the evidence was rated according to the GRADE evidence evaluation framework: the evidence levels were based on a systematic review of the literature, and the recommendation grades were classified as either strong or weak. The applicability of the guidelines was considered to meet patients' view and preferences in the context of Korea. The topics of the guidelines cover diagnostic modalities (endoscopy, endoscopic ultrasound, and radiologic diagnosis), treatment modalities (surgery, therapeutic endoscopy, chemotherapy, and radiotherapy), and pathologic evaluation. An external review of the guidelines was conducted during the finalization phase.

Keywords

References

  1. Cancer statistics [Internet]. Goyang: National Cancer information Center [cited 2014 Feb 5]. Available from: http://www.cancer.go.kr/mbs/cancer/subview.jsp?id=cancer_040101000000.
  2. Cause of death statistics [Internet]. Daejeon: Korean Statistical Information Service [cited 2014 Feb 5]. Available from: http://kosis.kr/index/index.jsp.
  3. Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F, et al; International Stroke Trial Collaborative Group; European Carotid Surgery Trial Collaborative Group. Evaluating non-randomised intervention studies. Health Technol Assess 2003;7:iii-x, 1-173.
  4. Turk DJ, Kozarek RA, Botoman VA, Patterson DJ, Ball TJ. Disposable endoscopic biopsy forceps: comparison with standard forceps of sample size and adequacy of specimen. J Clin Gastroenterol 1991;13:76-78. https://doi.org/10.1097/00004836-199102000-00016
  5. Dandalides SM, Carey WD, Petras R, Achkar E. Endoscopic small bowel mucosal biopsy: a controlled trial evaluating forceps size and biopsy location in the diagnosis of normal and abnormal mucosal architecture. Gastrointest Endosc 1989;35:197-200. https://doi.org/10.1016/S0016-5107(89)72757-7
  6. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003;3:25. https://doi.org/10.1186/1471-2288-3-25
  7. Yang R, Vuitch F, Wright K, McCarthy J. Adequacy of disposable biopsy forceps for gastrointestinal endoscopy: a direct comparison with reusable forceps. Gastrointest Endosc 1990;36:379-381. https://doi.org/10.1016/S0016-5107(90)71069-3
  8. Guyatt GH, Oxman AD, Kunz R, Jaeschke R, Helfand M, Liberati A, et al; GRADE Working Group. Incorporating considerations of resources use into grading recommendations. BMJ 2008;336:1170-1173. https://doi.org/10.1136/bmj.39504.506319.80
  9. Kobayashi S, Kasugai T, Yamazaki H. Endoscopic differentiation of early gastric cancer from benign peptic ulcer. Gastrointest Endosc 1979;25:55-57. https://doi.org/10.1016/S0016-5107(79)73360-8
  10. Ryu KW, Lee JH, Choi IJ, Bae JM. Preoperative endoscopic clipping: localizing technique of early gastric cancer. J Surg Oncol 2003;82:75-77. https://doi.org/10.1002/jso.10191
  11. Park DJ, Lee HJ, Kim SG, Jung HC, Song IS, Lee KU, et al. Intraoperative gastroscopy for gastric surgery. Surg Endosc 2005;19:1358-1361. https://doi.org/10.1007/s00464-004-2217-0
  12. Shim CS. Staining in gastrointestinal endoscopy: clinical applications and limitations. Endoscopy 1999;31:487-496. https://doi.org/10.1055/s-1999-46
  13. Mocellin S, Marchet A, Nitti D. EUS for the staging of gastric cancer: a meta-analysis. Gastrointest Endosc 2011;73:1122-1134. https://doi.org/10.1016/j.gie.2011.01.030
  14. Choi J, Kim SG, Im JP, Kim JS, Jung HC, Song IS. Comparison of endoscopic ultrasonography and conventional endoscopy for prediction of depth of tumor invasion in early gastric cancer. Endoscopy 2010;42:705-713. https://doi.org/10.1055/s-0030-1255617
  15. Low VH, Levine MS, Rubesin SE, Laufer I, Herlinger H. Diagnosis of gastric carcinoma: sensitivity of double-contrast barium studies. AJR Am J Roentgenol 1994;162:329-334. https://doi.org/10.2214/ajr.162.2.8310920
  16. Murakami R, Tsukuma H, Ubukata T, Nakanishi K, Fujimoto I, Kawashima T, et al. Estimation of validity of mass screening program for gastric cancer in Osaka, Japan. Cancer 1990;65:1255-1260. https://doi.org/10.1002/1097-0142(19900301)65:5<1255::AID-CNCR2820650536>3.0.CO;2-P
  17. Gelfand DW. The multiphasic upper gastrointestinal examination. Radiol Clin North Am 1994;32:1067-1081.
  18. Chen CY, Hsu JS, Wu DC, Kang WY, Hsieh JS, Jaw TS, et al. Gastric cancer: preoperative local staging with 3D multi-detector row CT--correlation with surgical and histopathologic results. Radiology 2007;242:472-482. https://doi.org/10.1148/radiol.2422051557
  19. Kim JH, Eun HW, Hong SS, Auh YH. Early gastric cancer: virtual gastroscopy. Abdom Imaging 2006;31:507-513. https://doi.org/10.1007/s00261-005-0183-1
  20. Kim HJ, Kim AY, Oh ST, Kim JS, Kim KW, Kim PN, et al. Gastric cancer staging at multi-detector row CT gastrography: comparison of transverse and volumetric CT scanning. Radiology 2005;236:879-885. https://doi.org/10.1148/radiol.2363041101
  21. Kumano S, Murakami T, Kim T, Hori M, Iannaccone R, Nakata S, et al. T staging of gastric cancer: role of multi-detector row CT. Radiology 2005;237:961-966. https://doi.org/10.1148/radiol.2373041380
  22. Makino T, Fujiwara Y, Takiguchi S, Tsuboyama T, Kim T, Nushijima Y, et al. Preoperative T staging of gastric cancer by multi-detector row computed tomography. Surgery 2011;149:672-679. https://doi.org/10.1016/j.surg.2010.12.003
  23. Park SR, Kim MJ, Ryu KW, Lee JH, Lee JS, Nam BH, et al. Prognostic value of preoperative clinical staging assessed by computed tomography in resectable gastric cancer patients: a viewpoint in the era of preoperative treatment. Ann Surg 2010;251:428-435. https://doi.org/10.1097/SLA.0b013e3181ca69a7
  24. Yan C, Zhu ZG, Yan M, Zhang H, Pan ZL, Chen J, et al. Value of multidetector-row computed tomography in the preoperative T and N staging of gastric carcinoma: a large-scale Chinese study. J Surg Oncol 2009;100:205-214. https://doi.org/10.1002/jso.21316
  25. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247. https://doi.org/10.1016/j.ejca.2008.10.026
  26. Goshima S, Kanematsu M, Watanabe H, Kondo H, Shiratori Y, Onozuka M, et al. Hepatic hemangioma and metastasis: differentiation with gadoxetate disodium-enhanced 3-T MRI. AJR Am J Roentgenol 2010;195:941-946. https://doi.org/10.2214/AJR.09.3730
  27. Shoda H, Kakugawa Y, Saito D, Kozu T, Terauchi T, Daisaki H, et al. Evaluation of 18F-2-deoxy-2-fluoro-glucose positron emission tomography for gastric cancer screening in asymptomatic individuals undergoing endoscopy. Br J Cancer 2007;97:1493-1498. https://doi.org/10.1038/sj.bjc.6604062
  28. Delbeke D, Martin WH. Positron emission tomography imaging in oncology. Radiol Clin North Am 2001;39:883-917. https://doi.org/10.1016/S0033-8389(05)70319-5
  29. Yoshioka T, Yamaguchi K, Kubota K, Saginoya T, Yamazaki T, Ido T, et al. Evaluation of 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer. J Nucl Med 2003;44:690-699.
  30. Buyyounouski MK, Klump WJ, Konski A, Wu H, Adler LP. FDG PET imaging of signet-ring cell adenocarcinoma of the stomach. Clin Nucl Med 2005;30:118-119. https://doi.org/10.1097/00003072-200502000-00014
  31. Mochiki E, Kuwano H, Katoh H, Asao T, Oriuchi N, Endo K. Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. World J Surg 2004;28:247-253. https://doi.org/10.1007/s00268-003-7191-5
  32. Stahl A, Ott K, Weber WA, Becker K, Link T, Siewert JR, et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 2003;30:288-295. https://doi.org/10.1007/s00259-002-1029-5
  33. De Potter T, Flamen P, Van Cutsem E, Penninckx F, Filez L, Bormans G, et al. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer. Eur J Nucl Med Mol Imaging 2002;29:525-529. https://doi.org/10.1007/s00259-001-0743-8
  34. Yun M, Lim JS, Noh SH, Hyung WJ, Cheong JH, Bong JK, et al. Lymph node staging of gastric cancer using (18)F-FDG PET: a comparison study with CT. J Nucl Med 2005;46:1582-1588.
  35. Hillner BE, Siegel BA, Shields AF, Liu D, Gareen IF, Hunt E, et al. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry. J Nucl Med 2008;49:1928-1935. https://doi.org/10.2967/jnumed.108.056713
  36. Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 2002;224:748-756. https://doi.org/10.1148/radiol.2243011362
  37. Turlakow A, Yeung HW, Salmon AS, Macapinlac HA, Larson SM. Peritoneal carcinomatosis: role of (18)F-FDG PET. J Nucl Med 2003;44:1407-1412.
  38. Jadvar H, Tatlidil R, Garcia AA, Conti PS. Evaluation of recurrent gastric malignancy with [F-18]-FDG positron emission tomography. Clin Radiol 2003;58:215-221. https://doi.org/10.1016/S0009-9260(02)00477-4
  39. Ott K, Fink U, Becker K, Stahl A, Dittler HJ, Busch R, et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 2003;21:4604-4610. https://doi.org/10.1200/JCO.2003.06.574
  40. Bilici A, Ustaalioglu BB, Seker M, Kefeli U, Canpolat N, Tekinsoy B, et al. The role of $^{18}F$-FDG PET/CT in the assessment of suspected recurrent gastric cancer after initial surgical resection: can the results of FDG PET/CT influence patients' treatment decision making? Eur J Nucl Med Mol Imaging 2011;38:64-73. https://doi.org/10.1007/s00259-010-1611-1
  41. Harrison LE, Karpeh MS, Brennan MF. Total gastrectomy is not necessary for proximal gastric cancer. Surgery 1998;123:127-130. https://doi.org/10.1016/S0039-6060(98)70248-X
  42. An JY, Youn HG, Choi MG, Noh JH, Sohn TS, Kim S. The difficult choice between total and proximal gastrectomy in proximal early gastric cancer. Am J Surg 2008;196:587-591. https://doi.org/10.1016/j.amjsurg.2007.09.040
  43. Ooki A, Yamashita K, Kikuchi S, Sakuramoto S, Katada N, Hutawatari N, et al. Clinical significance of total gastrectomy for proximal gastric cancer. Anticancer Res 2008;28:2875-2883.
  44. Yoo CH, Sohn BH, Han WK, Pae WK. Proximal gastrectomy reconstructed by jejunal pouch interposition for upper third gastric cancer: prospective randomized study. World J Surg 2005;29:1592-1599. https://doi.org/10.1007/s00268-005-7793-1
  45. The Korean Gastric Cancer Association, ed. Gastric cancer and gastrointestinal disease. Seoul: Ilchokak, 2011.
  46. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer 2011;14:113-123. https://doi.org/10.1007/s10120-011-0042-4
  47. Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, et al; Japan Clinical Oncology Group. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 2008;359:453-462. https://doi.org/10.1056/NEJMoa0707035
  48. Nunobe S, Hiki N, Ohyama S, Fukunaga T, Seto Y, Yamaguchi T. Survival benefits of pancreatoduodenectomy for gastric cancer: relationship to the number of lymph node metastases. Langenbecks Arch Surg 2008;393:157-162. https://doi.org/10.1007/s00423-007-0248-4
  49. Shchepotin IB, Chorny VA, Nauta RJ, Shabahang M, Buras RR, Evans SR. Extended surgical resection in T4 gastric cancer. Am J Surg 1998;175:123-126. https://doi.org/10.1016/S0002-9610(97)00268-7
  50. Maehara Y, Oiwa H, Tomisaki S, Sakaguchi Y, Watanabe A, Anai H, et al. Prognosis and surgical treatment of gastric cancer invading the pancreas. Oncology 2000;59:1-6.
  51. Mita K, Ito H, Fukumoto M, Murabayashi R, Koizumi K, Hayashi T, et al. Surgical outcomes and survival after extended multiorgan resection for T4 gastric cancer. Am J Surg 2012;203:107-111. https://doi.org/10.1016/j.amjsurg.2010.12.007
  52. Ozer I, Bostanci EB, Orug T, Ozogul YB, Ulas M, Ercan M, et al. Surgical outcomes and survival after multiorgan resection for locally advanced gastric cancer. Am J Surg 2009;198:25-30. https://doi.org/10.1016/j.amjsurg.2008.06.031
  53. Jeong O, Choi WY, Park YK. Appropriate selection of patients for combined organ resection in cases of gastric carcinoma invading adjacent organs. J Surg Oncol 2009;100:115-120. https://doi.org/10.1002/jso.21306
  54. Carboni F, Lepiane P, Santoro R, Lorusso R, Mancini P, Sperduti I, et al. Extended multiorgan resection for T4 gastric carcinoma: 25-year experience. J Surg Oncol 2005;90:95-100. https://doi.org/10.1002/jso.20244
  55. Onate-Ocana LF, Becker M, Carrillo JF, Aiello-Crocifoglio V, Gallardo-Rincon D, Brom-Valladares R, et al. Selection of best candidates for multiorgan resection among patients with T4 gastric carcinoma. J Surg Oncol 2008;98:336-342. https://doi.org/10.1002/jso.21118
  56. Kobayashi A, Nakagohri T, Konishi M, Inoue K, Takahashi S, Itou M, et al. Aggressive surgical treatment for T4 gastric cancer. J Gastrointest Surg 2004;8:464-470. https://doi.org/10.1016/j.gassur.2003.12.018
  57. Kunisaki C, Akiyama H, Nomura M, Matsuda G, Otsuka Y, Ono HA, et al. Surgical outcomes in patients with T4 gastric carcinoma. J Am Coll Surg 2006;202:223-230. https://doi.org/10.1016/j.jamcollsurg.2005.10.020
  58. Martin RC 2nd, Jaques DP, Brennan MF, Karpeh M. Extended local resection for advanced gastric cancer: increased survival versus increased morbidity. Ann Surg 2002;236:159-165. https://doi.org/10.1097/00000658-200208000-00003
  59. Shin SH, Jung H, Choi SH, An JY, Choi MG, Noh JH, et al. Clinical significance of splenic hilar lymph node metastasis in proximal gastric cancer. Ann Surg Oncol 2009;16:1304-1309. https://doi.org/10.1245/s10434-009-0389-5
  60. Sano T, Yamamoto S, Sasako M; Japan Clinical Oncology Group Study LCOG 0110-MF. Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma: Japan clinical oncology group study JCOG 0110-MF. Jpn J Clin Oncol 2002;32:363-364. https://doi.org/10.1093/jjco/hyf085
  61. Yu W, Choi GS, Chung HY. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg 2006;93:559-563. https://doi.org/10.1002/bjs.5353
  62. Kunisaki C, Makino H, Suwa H, Sato T, Oshima T, Nagano Y, et al. Impact of splenectomy in patients with gastric adenocarcinoma of the cardia. J Gastrointest Surg 2007;11:1039-1044. https://doi.org/10.1007/s11605-007-0186-z
  63. Cheong JH, Hyung WJ, Chen J, Kim J, Choi SH, Noh SH. Survival benefit of metastasectomy for Krukenberg tumors from gastric cancer. Gynecol Oncol 2004;94:477-482. https://doi.org/10.1016/j.ygyno.2004.05.007
  64. Okano K, Maeba T, Ishimura K, Karasawa Y, Goda F, Wakabayashi H, et al. Hepatic resection for metastatic tumors from gastric cancer. Ann Surg 2002;235:86-91. https://doi.org/10.1097/00000658-200201000-00011
  65. Cheon SH, Rha SY, Jeung HC, Im CK, Kim SH, Kim HR, et al. Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases. Ann Oncol 2008;19:1146-1153. https://doi.org/10.1093/annonc/mdn026
  66. Glehen O, Mithieux F, Osinsky D, Beaujard AC, Freyer G, Guertsch P, et al. Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. J Clin Oncol 2003;21:799-806. https://doi.org/10.1200/JCO.2003.06.139
  67. Chareton B, Landen S, Manganas D, Meunier B, Launois B. Prospective randomized trial comparing Billroth I and Billroth II procedures for carcinoma of the gastric antrum. J Am Coll Surg 1996;183:190-194.
  68. Kang KC, Cho GS, Han SU, Kim W, Kim HH, Kim MC, et al; Korean Laparoscopic Gastrointestinal Surgery Study (KLASS) Group. Comparison of Billroth I and Billroth II reconstructions after laparoscopy-assisted distal gastrectomy: a retrospective analysis of large-scale multicenter results from Korea. Surg Endosc 2011;25:1953-1961. https://doi.org/10.1007/s00464-010-1493-0
  69. Kojima K, Yamada H, Inokuchi M, Kawano T, Sugihara K. A comparison of Roux-en-Y and Billroth-I reconstruction after laparoscopy-assisted distal gastrectomy. Ann Surg 2008;247:962-967. https://doi.org/10.1097/SLA.0b013e31816d9526
  70. Kim JP, Hur YS, Yang HK. Lymph node metastasis as a significant prognostic factor in early gastric cancer: analysis of 1,136 early gastric cancers. Ann Surg Oncol 1995;2:308-313. https://doi.org/10.1007/BF02307062
  71. An JY, Baik YH, Choi MG, Noh JH, Sohn TS, Kim S. Predictive factors for lymph node metastasis in early gastric cancer with submucosal invasion: analysis of a single institutional experience. Ann Surg 2007;246:749-753. https://doi.org/10.1097/SLA.0b013e31811f3fb7
  72. Lai JF, Kim S, Kim K, Li C, Oh SJ, Hyung WJ, et al. Prediction of recurrence of early gastric cancer after curative resection. Ann Surg Oncol 2009;16:1896-1902. https://doi.org/10.1245/s10434-009-0473-x
  73. Youn HG, An JY, Choi MG, Noh JH, Sohn TS, Kim S. Recurrence after curative resection of early gastric cancer. Ann Surg Oncol 2010;17:448-454. https://doi.org/10.1245/s10434-009-0772-2
  74. Kim MC, Kim W, Kim HH, Ryu SW, Ryu SY, Song KY, et al; Korean Laparoscopic Gastrointestinal Surgery Study (KLASS) Group. Risk factors associated with complication following laparoscopy-assisted gastrectomy for gastric cancer: a large-scale Korean multicenter study. Ann Surg Oncol 2008;15:2692-2700. https://doi.org/10.1245/s10434-008-0075-z
  75. Song J, Lee HJ, Cho GS, Han SU, Kim MC, Ryu SW, et al; Korean Laparoscopic Gastrointestinal Surgery Study (KLASS) Group. Recurrence following laparoscopy-assisted gastrectomy for gastric cancer: a multicenter retrospective analysis of 1,417 patients. Ann Surg Oncol 2010;17:1777-1786. https://doi.org/10.1245/s10434-010-0932-4
  76. Kitano S, Shiraishi N, Uyama I, Sugihara K, Tanigawa N; Japanese Laparoscopic Surgery Study Group. A multicenter study on oncologic outcome of laparoscopic gastrectomy for early cancer in Japan. Ann Surg 2007;245:68-72. https://doi.org/10.1097/01.sla.0000225364.03133.f8
  77. Huscher CG, Mingoli A, Sgarzini G, Brachini G, Binda B, Di Paola M, et al. Totally laparoscopic total and subtotal gastrectomy with extended lymph node dissection for early and advanced gastric cancer: early and long-term results of a 100-patient series. Am J Surg 2007;194:839-844; discussion 844. https://doi.org/10.1016/j.amjsurg.2007.08.037
  78. Fujiwara M, Kodera Y, Misawa K, Kinoshita M, Kinoshita T, Miura S, et al. Longterm outcomes of early-stage gastric carcinoma patients treated with laparoscopy-assisted surgery. J Am Coll Surg 2008;206:138-143. https://doi.org/10.1016/j.jamcollsurg.2007.07.013
  79. Hwang SH, Park do J, Jee YS, Kim MC, Kim HH, Lee HJ, et al. Actual 3-year survival after laparoscopy-assisted gastrectomy for gastric cancer. Arch Surg 2009;144:559-564; discussion https://doi.org/10.1001/archsurg.2009.110
  80. Lee SW, Nomura E, Bouras G, Tokuhara T, Tsunemi S, Tanigawa N. Long-term oncologic outcomes from laparoscopic gastrectomy for gastric cancer: a single-center experience of 601 consecutive resections. J Am Coll Surg 2010;211:33-40. https://doi.org/10.1016/j.jamcollsurg.2010.03.018
  81. Pugliese R, Maggioni D, Sansonna F, Costanzi A, Ferrari GC, Di Lernia S, et al. Subtotal gastrectomy with D2 dissection by minimally invasive surgery for distal adenocarcinoma of the stomach: results and 5-year survival. Surg Endosc 2010;24:2594-2602. https://doi.org/10.1007/s00464-010-1014-1
  82. Jiang X, Hiki N, Nunobe S, Fukunaga T, Kumagai K, Nohara K, et al. Long-term outcome and survival with laparoscopy-assisted pylorus-preserving gastrectomy for early gastric cancer. Surg Endosc 2011;25:1182-1186. https://doi.org/10.1007/s00464-010-1336-z
  83. Yoo HM, Lee HH, Shim JH, Jeon HM, Park CH, Kim JG, et al. Long-term outcomes and survival after laparoscopy-assisted distal gastrectomy for gastric cancer: three-year survival analysis of a single-center experience in Korea. J Surg Oncol 2011;104:511-515. https://doi.org/10.1002/jso.21982
  84. Pak KH, Hyung WJ, Son T, Obama K, Woo Y, Kim HI, et al. Long-term oncologic outcomes of 714 consecutive laparoscopic gastrectomies for gastric cancer: results from the 7-year experience of a single institute. Surg Endosc 2012;26:130-136. https://doi.org/10.1007/s00464-011-1838-3
  85. Hur H, Jeon HM, Kim W. Laparoscopy-assisted distal gastrectomy with D2 lymphadenectomy for T2b advanced gastric cancers: three years' experience. J Surg Oncol 2008;98:515-519. https://doi.org/10.1002/jso.21155
  86. Kim HH, Hyung WJ, Cho GS, Kim MC, Han SU, Kim W, et al. Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer: an interim report--a phase III multicenter, prospective, randomized Trial (KLASS Trial). Ann Surg 2010;251:417-420. https://doi.org/10.1097/SLA.0b013e3181cc8f6b
  87. Sano T. Evaluation of the gastric cancer treatment guidelines of the Japanese Gastric Cancer Association. Gan To Kagaku Ryoho 2010;37:582-586.
  88. Sasaki T. Discussion for gastric cancer treatment guidelines in Japan. Nihon Rinsho 2003;61:13-18.
  89. Kahlke V, Bestmann B, Schmid A, Doniec JM, Kuchler T, Kremer B. Palliation of metastatic gastric cancer: impact of preoperative symptoms and the type of operation on survival and quality of life. World J Surg 2004;28:369-375. https://doi.org/10.1007/s00268-003-7119-0
  90. Sarela AI, Yelluri S; Leeds Upper Gastrointestinal Cancer Multidisciplinary Team. Gastric adenocarcinoma with distant metastasis: is gastrectomy necessary? Arch Surg 2007;142:143-149; discussion 149. https://doi.org/10.1001/archsurg.142.2.143
  91. Ono H, Kondo H, Gotoda T, Shirao K, Yamaguchi H, Saito D, et al. Endoscopic mucosal resection for treatment of early gastric cancer. Gut 2001;48:225-229. https://doi.org/10.1136/gut.48.2.225
  92. Manner H, Rabenstein T, May A, Pech O, Gossner L, Werk D, et al. Long-term results of endoscopic resection in early gastric cancer: the Western experience. Am J Gastroenterol 2009;104:566-573. https://doi.org/10.1038/ajg.2008.151
  93. Choi KS, Jung HY, Choi KD, Lee GH, Song HJ, Kim do H, et al. EMR versus gastrectomy for intramucosal gastric cancer: comparison of long-term outcomes. Gastrointest Endosc 2011;73:942-948. https://doi.org/10.1016/j.gie.2010.12.032
  94. Jang JS, Choi SR, Qureshi W, Kim MC, Kim SJ, Jeung JS, et al. Long-term outcomes of endoscopic submucosal dissection in gastric neoplastic lesions at a single institution in South Korea. Scand J Gastroenterol 2009;44:1315-1322. https://doi.org/10.3109/00365520903254304
  95. Uedo N, Iishi H, Tatsuta M, Ishihara R, Higashino K, Takeuchi Y, et al. Longterm outcomes after endoscopic mucosal resection for early gastric cancer. Gastric Cancer 2006;9:88-92. https://doi.org/10.1007/s10120-005-0357-0
  96. Gotoda T, Iwasaki M, Kusano C, Seewald S, Oda I. Endoscopic resection of early gastric cancer treated by guideline and expanded National Cancer Centre criteria. Br J Surg 2010;97:868-871. https://doi.org/10.1002/bjs.7033
  97. Bennett C, Wang Y, Pan T. Endoscopic mucosal resection for early gastric cancer. Cochrane Database Syst Rev 2009;(4):CD004276.
  98. Chung JW, Jung HY, Choi KD, Song HJ, Lee GH, Jang SJ, et al. Extended indication of endoscopic resection for mucosal early gastric cancer: analysis of a single center experience. J Gastroenterol Hepatol 2011;26:884-887. https://doi.org/10.1111/j.1440-1746.2010.06611.x
  99. Kang HJ, Kim DH, Jeon TY, Lee SH, Shin N, Chae SH, et al. Lymph node metastasis from intestinal-type early gastric cancer: experience in a single institution and reassessment of the extended criteria for endoscopic submucosal dissection. Gastrointest Endosc 2010;72:508-515. https://doi.org/10.1016/j.gie.2010.03.1077
  100. Soetikno R, Kaltenbach T, Yeh R, Gotoda T. Endoscopic mucosal resection for early cancers of the upper gastrointestinal tract. J Clin Oncol 2005;23:4490-4498. https://doi.org/10.1200/JCO.2005.19.935
  101. Song SY, Park S, Kim S, Son HJ, Rhee JC. Characteristics of intramucosal gastric carcinoma with lymph node metastatic disease. Histopathology 2004;44:437-444. https://doi.org/10.1111/j.1365-2559.2004.01870.x
  102. Hyung WJ, Cheong JH, Kim J, Chen J, Choi SH, Noh SH. Application of minimally invasive treatment for early gastric cancer. J Surg Oncol 2004;85:181-185; discussion 186. https://doi.org/10.1002/jso.20018
  103. Lee H, Yun WK, Min BH, Lee JH, Rhee PL, Kim KM, et al. A feasibility study on the expanded indication for endoscopic submucosal dissection of early gastric cancer. Surg Endosc 2011;25:1985-1993. https://doi.org/10.1007/s00464-010-1499-7
  104. Ahn JY, Jung HY, Choi KD, Choi JY, Kim MY, Lee JH, et al. Endoscopic and oncologic outcomes after endoscopic resection for early gastric cancer: 1370 cases of absolute and extended indications. Gastrointest Endosc 2011;74:485-493. https://doi.org/10.1016/j.gie.2011.04.038
  105. Ajani JA, Barthel JS, Bekaii-Saab T, Bentrem DJ, D'Amico TA, Das P, et al; NCCN Gastric Cancer Panel. Gastric cancer. J Natl Compr Canc Netw 2010;8:378-409. https://doi.org/10.6004/jnccn.2010.0030
  106. Roviello F, Marrelli D, de Manzoni G, Morgagni P, Di Leo A, Saragoni L, et al; Italian Research Group for Gastric Cancer. Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg 2003;90:1113-1119. https://doi.org/10.1002/bjs.4164
  107. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg 2000;87:236-242. https://doi.org/10.1046/j.1365-2168.2000.01360.x
  108. Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 1999;35:1059-1064. https://doi.org/10.1016/S0959-8049(99)00076-3
  109. Mari E, Floriani I, Tinazzi A, Buda A, Belfiglio M, Valentini M, et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol 2000;11:837-843. https://doi.org/10.1023/A:1008377101672
  110. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010;303:1729-1737. https://doi.org/10.1001/jama.2010.534
  111. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20. https://doi.org/10.1056/NEJMoa055531
  112. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al; ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-1820. https://doi.org/10.1056/NEJMoa072252
  113. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011;29:4387-4393. https://doi.org/10.1200/JCO.2011.36.5908
  114. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al; CLASSIC trial investigators. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012;379:315-321. https://doi.org/10.1016/S0140-6736(11)61873-4
  115. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24:2903-2909. https://doi.org/10.1200/JCO.2005.05.0245
  116. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997;8:163-168. https://doi.org/10.1023/A:1008243606668
  117. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41. https://doi.org/10.1002/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P
  118. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-591. https://doi.org/10.1038/bjc.1995.114
  119. Cocconi G, DeLisi V, Di Blasio B. Randomized comparison of 5-FU alone or combined with mitomycin and cytarabine (MFC) in the treatment of advanced gastric cancer. Cancer Treat Rep 1982;66:1263-1266.
  120. Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Krook JE, Everson LK, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA 1985;253:2061-2067. https://doi.org/10.1001/jama.1985.03350380077025
  121. Douglass HO Jr, Lavin PT, Goudsmit A, Klaassen DJ, Paul AR. An Eastern Cooperative Oncology Group evaluation of combinations of methyl-CCNU, mitomycin C, Adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST 2277). J Clin Oncol 1984;2:1372-1381. https://doi.org/10.1200/JCO.1984.2.12.1372
  122. The Gastrointestinal Tumor study Group. A comparative clinical assessment of combination chemotherapy in the management of advanced gastric carcinoma: The Gastrointestinal Tumor study Group. Cancer 1982;49:1362-1366. https://doi.org/10.1002/1097-0142(19820401)49:7<1362::AID-CNCR2820490710>3.0.CO;2-Q
  123. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-697. https://doi.org/10.1016/S0140-6736(10)61121-X
  124. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011;29:3968-3976. https://doi.org/10.1200/JCO.2011.36.2236
  125. Lordick F, Kang YK, Salman P, Oh SC, Bodoky G, Kurteva GP, et al. Clinical outcome according to tumor HER2 status and EGFR expression in advanced gastric cancer patients from the EXPAND study. ASCO Meeting Abstracts 2013;31 Suppl:4021.
  126. Hecht JR, Bang YJ, Qin S, Chung HC, Xu JM, Park JO, et al. Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial. ASCO Meeting Abstracts 2013;31 Suppl:LBA4001.
  127. Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 2011;47:2306-2314. https://doi.org/10.1016/j.ejca.2011.06.002
  128. Park SH, Lim DH, Park K, Lee S, Oh SY, Kwon H, et al. A multicenter, randomized phase III trial comparing second-line chemotherapy (SLC) plus best supportive case (BSC) with BSC alone for pretreated advanced gastric cancer (AGC). ASCO Annual Meeting Proceedings 2011;29 Suppl:abstr 4004.
  129. Zhang ZX, Gu XZ, Yin WB, Huang GJ, Zhang DW, Zhang RG. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC)--report on 370 patients. Int J Radiat Oncol Biol Phys 1998;42:929-934. https://doi.org/10.1016/S0360-3016(98)00280-6
  130. Skoropad VY, Berdov BA, Mardynski YS, Titova LN. A prospective, randomized trial of pre-operative and intraoperative radiotherapy versus surgery alone in resectable gastric cancer. Eur J Surg Oncol 2000;26:773-779. https://doi.org/10.1053/ejso.2000.1002
  131. Skoropad V, Berdov B, Zagrebin V. Concentrated preoperative radiotherapy for resectable gastric cancer: 20-years follow-up of a randomized trial. J Surg Oncol 2002;80:72-78. https://doi.org/10.1002/jso.10102
  132. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-730. https://doi.org/10.1056/NEJMoa010187
  133. Kim S, Lim DH, Lee J, Kang WK, MacDonald JS, Park CH, et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 2005;63:1279-1285. https://doi.org/10.1016/j.ijrobp.2005.05.005
  134. Dikken JL, Jansen EP, Cats A, Bakker B, Hartgrink HH, Kranenbarg EM, et al. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol 2010;28:2430-2436. https://doi.org/10.1200/JCO.2009.26.9654
  135. The Study Group for Gastrointestinal Pathology, Korean Society of Pathologists. Guidelines for Pathologic Study of Gastric Cancer. Korean J Pathol 1992;26:154-163.
  136. International Agency for Research on Cancer, ed. WHO classification of tumors of the digestive system. 4th ed. Lyon: World Health Organization, 2010.
  137. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965;64:31-49. https://doi.org/10.1111/apm.1965.64.1.31
  138. Kim WH, Park CK, Kim YB, Kim YW, Kim HG, Bae HI, et al. A standardized pathology report for gastric cancer. Korean J Pathol 2005;39:106-113.
  139. Edge SB; American Joint Committee on Cancer, eds. AJCC Cancer Staging Manual. 7th ed. New York (NY): Springer, 2010.
  140. Kim A, Bae JM, Kim SW, Gu MJ, Bae YK. HER2 status in gastric adenocarcinomas assessed by immunohistochemistry, automated silver-enhanced in situ hybridization and fluorescence in situ hybridization. Korean J Pathol 2010;44:493-501. https://doi.org/10.4132/KoreanJPathol.2010.44.5.493
  141. Kim MA, Jung EJ, Lee HS, Lee HE, Jeon YK, Yang HK, et al. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Hum Pathol 2007;38:1386-1393. https://doi.org/10.1016/j.humpath.2007.02.005
  142. Bilous M, Osamura RY, Ruschoff J, van de Vijver M, Hanna W, Penault-Llorca F, et al. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol 2010;41:304-305; author reply 305-306. https://doi.org/10.1016/j.humpath.2009.10.006
  143. Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52:797-805. https://doi.org/10.1111/j.1365-2559.2008.03028.x
  144. Yano T, Doi T, Ohtsu A, Boku N, Hashizume K, Nakanishi M, et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 2006;15:65-71.

Cited by

  1. Expanding Indications of Endoscopic Submucosal Dissection for Early Gastric Cancer: Hope or Hype? vol.9, pp.2, 2014, https://doi.org/10.5009/gnl15008
  2. Adjuvant and Neoadjuvant Options in Resectable Gastric Cancer: Is There an Optimal Treatment Approach? vol.17, pp.4, 2014, https://doi.org/10.1007/s11912-015-0442-4
  3. Beginner Surgeon's Initial Experience with Distal Subtotal Gastrectomy for Gastric Cancer Using a Minimally Invasive Approach vol.15, pp.4, 2015, https://doi.org/10.5230/jgc.2015.15.4.270
  4. Long-term outcomes of endoscopic submucosal dissection for early gastric cancer: a comparison study to surgery using propensity score-matched analysis vol.30, pp.9, 2016, https://doi.org/10.1007/s00464-015-4672-1
  5. Diagnostic group classifications of gastric neoplasms by endoscopic resection criteria before and after treatment: real-world experience vol.30, pp.9, 2016, https://doi.org/10.1007/s00464-015-4710-z
  6. Feasibility of Laparoscopic Radical Gastrectomy for Gastric Cancer of Clinical Stage II or Higher: Early Outcomes in a Phase II Study (KUGC04) vol.23, pp.4, 2014, https://doi.org/10.1245/s10434-016-5383-0
  7. Mixed Carcinoma as an Independent Prognostic Factor in Submucosal Invasive Gastric Carcinoma vol.31, pp.6, 2014, https://doi.org/10.3346/jkms.2016.31.6.866
  8. Gastric cancer: Current status of lymph node dissection vol.22, pp.10, 2016, https://doi.org/10.3748/wjg.v22.i10.2875
  9. Recent developments and innovations in gastric cancer vol.22, pp.17, 2016, https://doi.org/10.3748/wjg.v22.i17.4307
  10. Feasibility study on expanded indication for endoscopic submucosal dissection of intramucosal poorly differentiated early gastric cancer vol.22, pp.29, 2016, https://doi.org/10.3748/wjg.v22.i29.6736
  11. Forkhead Transcription Factor FOXO1 Inhibits Angiogenesis in Gastric Cancer in Relation to SIRT1 vol.48, pp.1, 2014, https://doi.org/10.4143/crt.2014.247
  12. A phase II study of neoadjuvant chemotherapy with S‐1 and cisplatin for stage III gastric cancer: KUGC03 vol.113, pp.1, 2014, https://doi.org/10.1002/jso.24096
  13. Discrepancy between Clinical and Final Pathological Evaluation Findings in Early Gastric Cancer Patients Treated with Endoscopic Submucosal Dissection vol.16, pp.1, 2014, https://doi.org/10.5230/jgc.2016.16.1.34
  14. Primary Tumor 18F-FDG Avidity Affects the Performance of 18F-FDG PET/CT for Detecting Gastric Cancer Recurrence vol.57, pp.4, 2016, https://doi.org/10.2967/jnumed.115.163295
  15. Risk Factors of Submucosal or Lymphovascular Invasion in Early Gastric Cancer <2 cm vol.95, pp.22, 2014, https://doi.org/10.1097/md.0000000000003822
  16. Evaluation of rational extent lymphadenectomy for local advanced gastric cancer vol.28, pp.4, 2014, https://doi.org/10.21147/j.issn.1000-9604.2016.04.02
  17. Nomogram Incorporating CD44v6 and Clinicopathological Factors to Predict Lymph Node Metastasis for Early Gastric Cancer vol.11, pp.8, 2014, https://doi.org/10.1371/journal.pone.0159424
  18. The Korean Gastric Cancer Cohort Study: Study Protocol and Brief Results of a Large-Scale Prospective Cohort Study vol.16, pp.3, 2014, https://doi.org/10.5230/jgc.2016.16.3.182
  19. Clinical features of negative pathologic results after gastric endoscopic submucosal dissection vol.31, pp.3, 2014, https://doi.org/10.1007/s00464-016-5086-4
  20. Clinical outcomes of endoscopic submucosa dissection for high-grade dysplasia from endoscopic forceps biopsy vol.20, pp.4, 2014, https://doi.org/10.1007/s10120-016-0665-6
  21. Clinical application of early gastric carcinoma with lymphoid stroma based on lymph node metastasis status vol.20, pp.5, 2017, https://doi.org/10.1007/s10120-017-0703-z
  22. Incidence and Prognostic Value of Metastases to “Posterior” and Para-aortic Lymph Nodes in Resectable Gastric Cancer vol.24, pp.8, 2014, https://doi.org/10.1245/s10434-017-5857-8
  23. Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients vol.8, pp.16, 2014, https://doi.org/10.18632/oncotarget.15465
  24. Postoperative chemotherapy with S-1 plus oxaliplatin versus S-1 alone in locally advanced gastric cancer (RESCUE-GC study): a protocol for a phase III randomized controlled trial vol.29, pp.2, 2014, https://doi.org/10.21147/j.issn.1000-9604.2017.02.07
  25. Effects of 17β-estradiol and tamoxifen on gastric cancer cell proliferation and apoptosis and ER-α36 expression vol.13, pp.1, 2014, https://doi.org/10.3892/ol.2016.5424
  26. Expression of miR-711 and mechanism of proliferation and apoptosis in human gastric carcinoma vol.14, pp.4, 2017, https://doi.org/10.3892/ol.2017.6777
  27. Real-World Treatment Patterns among Patients with Advanced Gastric Cancer in South Korea vol.49, pp.3, 2014, https://doi.org/10.4143/crt.2016.001
  28. Therapeutic outcomes of endoscopic submucosal dissection for early gastric cancer: single-center study vol.29, pp.1, 2014, https://doi.org/10.1097/meg.0000000000000718
  29. The Effect of Endoscopic Resection on Short-Term Surgical Outcomes in Patients with Additional Laparoscopic Gastrectomy after Non-Curative Resection for Gastric Cancer vol.17, pp.1, 2017, https://doi.org/10.5230/jgc.2017.17.e4
  30. Extramural venous invasion detected by MDCT as an adverse imaging feature for predicting synchronous metastases in T4 gastric cancer vol.58, pp.4, 2017, https://doi.org/10.1177/0284185116658323
  31. Predictive factors to diagnosis undifferentiated early gastric cancer after endoscopic submucosal dissection vol.96, pp.36, 2014, https://doi.org/10.1097/md.0000000000008044
  32. Is it beneficial to perform surgical resection in elderly patients more than 80 years old with advanced gastric cancer? vol.52, pp.10, 2014, https://doi.org/10.1080/00365521.2017.1339828
  33. A Feasibility Study and Technical Tips for the Use of an Articulating Bipolar Vessel Sealer in da Vinci Robot-Assisted Gastrectomy vol.27, pp.11, 2014, https://doi.org/10.1089/lap.2017.0093
  34. Traditional Chinese medicine Ka-Sai-Ping suppresses the growths of gastric cancers via induction of autophagy vol.8, pp.56, 2014, https://doi.org/10.18632/oncotarget.18041
  35. Therapeutic Outcomes of Endoscopic Resection of Early Gastric Cancer with Undifferentiated-Type Histology: A Korean ESD Registry Database Analysis vol.50, pp.6, 2014, https://doi.org/10.5946/ce.2017.017
  36. Serial intermediate-term quality of life comparison after endoscopic submucosal dissection versus surgery in early gastric cancer patients vol.32, pp.4, 2014, https://doi.org/10.1007/s00464-017-5909-y
  37. Non-exposure simple suturing endoscopic full-thickness resection (NESS-EFTR) versus laparoscopic wedge resection: a randomized controlled trial in a porcine model vol.32, pp.5, 2018, https://doi.org/10.1007/s00464-017-5921-2
  38. Preoperative predictors of beyond endoscopic submucosal dissection indication or lymphovascular invasion in endoscopic resection for early gastric cancer vol.32, pp.6, 2014, https://doi.org/10.1007/s00464-017-6009-8
  39. Endoscopic Submucosal Dissection of Early Gastric Cancer in Patients with Liver Cirrhosis vol.63, pp.2, 2018, https://doi.org/10.1007/s10620-017-4814-5
  40. Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer vol.378, pp.12, 2014, https://doi.org/10.1056/nejmoa1708423
  41. Parameters for Predicting Surgical Outcomes for Gastric Cancer Patients: Simple Is Better Than Complex vol.25, pp.11, 2018, https://doi.org/10.1245/s10434-018-6684-2
  42. Gastric cancer combination therapy: synthesis of a hyaluronic acid and cisplatin containing lipid prodrug coloaded with sorafenib in a nanoparticulate system to exhibit enhanced anticancer efficacy an vol.12, pp.None, 2018, https://doi.org/10.2147/dddt.s176879
  43. AlPcS 4 -PDT for gastric cancer therapy using gold nanorod, cationic liposome, and Pluronic ® F127 nanomicellar drug carriers vol.13, pp.None, 2018, https://doi.org/10.2147/ijn.s154054
  44. Favoring D 2 -Lymphadenectomy in Gastric Cancer vol.5, pp.None, 2018, https://doi.org/10.3389/fsurg.2018.00042
  45. Effects of miR-21 on proliferation and apoptosis in human gastric adenocarcinoma cells vol.15, pp.1, 2014, https://doi.org/10.3892/ol.2017.6171
  46. Study of miR-143 expression in stomach cancer vol.16, pp.4, 2014, https://doi.org/10.3892/ol.2018.9173
  47. Outcomes of Endoscopic Submucosal Dissection for Early Gastric Cancer with Undifferentiated-Type Histology: A Clinical Simulation Using a Non-Selected Surgical Cohort vol.12, pp.3, 2014, https://doi.org/10.5009/gnl17247
  48. Indications and benefits of intraoperative esophagogastroduodenoscopy vol.13, pp.2, 2014, https://doi.org/10.5114/wiitm.2018.72740
  49. A Single-Center Experience of Endoscopic Resection for Early Gastric Cancer with Lymphoid Stroma vol.18, pp.4, 2014, https://doi.org/10.5230/jgc.2018.18.e40
  50. Neoadjuvant chemotherapy for gastric cancer. Is it a must or a fake? vol.24, pp.2, 2018, https://doi.org/10.3748/wjg.v24.i2.274
  51. The Prognostic Significance of Compliance with Postoperative Adjuvant Chemotherapy in Patients with Stage III Gastric Cancer: an Observational Study vol.18, pp.1, 2014, https://doi.org/10.5230/jgc.2018.18.e4
  52. A Case Report of Salvage Radiotherapy for a Patient with Recurrent Gastric Cancer and Multiple Comorbidities Using Real-time MRI-guided Adaptive Treatment System vol.10, pp.4, 2014, https://doi.org/10.7759/cureus.2471
  53. Clinical impact of molecular classifications in gastric cancer vol.70, pp.2, 2014, https://doi.org/10.1007/s13304-018-0546-0
  54. Para-aortic lymphadenectomy in surgery for gastric cancer: current indications and future perspectives vol.70, pp.2, 2014, https://doi.org/10.1007/s13304-018-0549-x
  55. Pathologic outcomes of endoscopic submucosal dissection for gastric epithelial neoplasia vol.97, pp.33, 2014, https://doi.org/10.1097/md.0000000000011802
  56. Cost Effectiveness of Gastric Cancer Screening According to Race and Ethnicity vol.155, pp.3, 2014, https://doi.org/10.1053/j.gastro.2018.05.026
  57. Characteristics of overlooked synchronous gastric epithelial neoplasia after endoscopic submucosal dissection vol.97, pp.39, 2014, https://doi.org/10.1097/md.0000000000012536
  58. A survey of early and advanced gastric cancer treatment by surgeons in Thailand vol.12, pp.2, 2018, https://doi.org/10.4081/oncol.2018.369
  59. Long-term Survival after Repeated Local Therapy and Salvage Chemotherapy for Recurrent Metastases from Gastric Cancer: a Case Report and Literature Review vol.18, pp.3, 2018, https://doi.org/10.5230/jgc.2018.18.e26
  60. Conversion surgery for gastric cancer patients: A review vol.10, pp.11, 2014, https://doi.org/10.4251/wjgo.v10.i11.398
  61. The distribution pattern of metastatic lymph nodes after non‐curative endoscopic resection in early gastric cancer vol.118, pp.8, 2014, https://doi.org/10.1002/jso.25279
  62. Endoscopic submucosal dissection of early gastric cancer with mixed-type histology : Protocol for a systematic review and meta-analysis vol.97, pp.51, 2014, https://doi.org/10.1097/md.0000000000013838
  63. Endoscopic submucosal dissection of papillary adenocarcinoma of stomach; protocol for a systematic review and meta-analysis vol.97, pp.52, 2014, https://doi.org/10.1097/md.0000000000013905
  64. Effect of total number of harvested lymph nodes on survival outcomes after curative resection for gastric adenocarcinoma: findings from an eastern high-volume gastric cancer center vol.18, pp.None, 2018, https://doi.org/10.1186/s12885-017-3872-6
  65. The predictive factors of gastric cancer recurrence after the completion of adjuvant chemotherapy in advanced gastric cancer vol.111, pp.None, 2014, https://doi.org/10.17235/reed.2019.6041/2018
  66. THERAPEUTIC TREATMENT OF STOMACH CANCER vol.2019, pp.1, 2014, https://doi.org/10.29254/2077-4214-2019-1-1-148-70-75
  67. Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach vol.19, pp.1, 2014, https://doi.org/10.5230/jgc.2019.19.e8
  68. Curcumin derivative L6H4 inhibits proliferation and invasion of gastric cancer cell line BGC‐823 vol.120, pp.1, 2014, https://doi.org/10.1002/jcb.27542
  69. Aberrant Cytokeratin 20 mRNA Expression in Peripheral Blood and Lymph Nodes Indicates Micrometastasis and Poor Prognosis in Patients With Gastric Carcinoma vol.18, pp.None, 2014, https://doi.org/10.1177/1533033819832856
  70. Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer vol.51, pp.1, 2014, https://doi.org/10.4143/crt.2018.073
  71. Pitfalls in the Interpretation of Publications about Endoscopic Submucosal Dissection of Early Gastric Cancer with Undifferentiated-Type Histology vol.52, pp.1, 2014, https://doi.org/10.5946/ce.2018.158
  72. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS vol.30, pp.1, 2014, https://doi.org/10.1093/annonc/mdy502
  73. Perilaldehyde activates AMP‐activated protein kinase to suppress the growth of gastric cancer via induction of autophagy vol.120, pp.2, 2014, https://doi.org/10.1002/jcb.27491
  74. Comparison of endoscopic submucosal dissection with surgical gastrectomy for early gastric cancer: An updated meta-analysis vol.11, pp.2, 2019, https://doi.org/10.4251/wjgo.v11.i2.161
  75. FDG PET/CT to predict the curability of endoscopic resection for early gastric cancer vol.145, pp.3, 2014, https://doi.org/10.1007/s00432-018-02832-9
  76. Cationic amino acid transporter PQLC 2 is a potential therapeutic target in gastric cancer vol.110, pp.4, 2014, https://doi.org/10.1111/cas.13966
  77. A Therapeutic Strategy for Chemotherapy-Resistant Gastric Cancer via Destabilization of Both β-Catenin and RAS vol.11, pp.4, 2019, https://doi.org/10.3390/cancers11040496
  78. Survival Benefit of Neoadjuvant Chemotherapy with S-1 Plus Docetaxel for Locally Advanced Gastric Cancer: A Propensity Score-Matched Analysis vol.26, pp.6, 2014, https://doi.org/10.1245/s10434-019-07299-7
  79. In Patients with Localized and Resectable Gastric Cancer, What is the Optimal Extent of Lymph Node Dissection-D1 Versus D2 Versus D3? vol.26, pp.9, 2019, https://doi.org/10.1245/s10434-019-07417-5
  80. Clinical Implementation of Precision Medicine in Gastric Cancer vol.19, pp.3, 2014, https://doi.org/10.5230/jgc.2019.19.e25
  81. Diagnosis and Management of Gastric Intestinal Metaplasia: Current Status and Future Directions vol.13, pp.6, 2014, https://doi.org/10.5009/gnl19181
  82. Possible indication of endoscopic resection in undifferentiated early gastric cancer vol.9, pp.1, 2014, https://doi.org/10.1038/s41598-019-53374-0
  83. 4.1B suppresses cancer cell proliferation by binding to EGFR P13 region of intracellular juxtamembrane segment vol.17, pp.1, 2014, https://doi.org/10.1186/s12964-019-0431-6
  84. Prognosis of proximal upper-third gastric cancer excluding tumors originating in the esophagogastric junction vol.15, pp.2, 2014, https://doi.org/10.14216/kjco.19017
  85. A Gastric Cancer Peptide GX1-Modified Nano-Lipid Carriers Encapsulating Paclitaxel: Design and Evaluation of Anti-Tumor Activity vol.14, pp.None, 2014, https://doi.org/10.2147/dddt.s233023
  86. Comparison of Treatment Modalities for Locally Advanced Gastric Cancer: A Propensity Score Matching Analysis vol.11, pp.15, 2020, https://doi.org/10.7150/jca.41082
  87. Endoscopic Submucosal Dissection of Early Gastric Cancer with Mixed-Type Histology: A Systematic Review vol.65, pp.1, 2014, https://doi.org/10.1007/s10620-019-05761-w
  88. National cancer screening program for gastric cancer in Korea: Nationwide treatment benefit and cost vol.126, pp.9, 2014, https://doi.org/10.1002/cncr.32753
  89. Factors associated with conversion to snare resection during gastric endoscopic submucosal dissection vol.34, pp.4, 2014, https://doi.org/10.1007/s00464-019-06918-4
  90. Endoscopic Factors that Can Predict Histological Ulcerations in Early Gastric Cancers vol.53, pp.3, 2014, https://doi.org/10.5946/ce.2019.133
  91. Differences in Factors Affecting the Quality of Life Over Time After the Gastrectomy in Patients With Stage I Gastric Cancer vol.43, pp.3, 2014, https://doi.org/10.1097/sga.0000000000000416
  92. Gastric cancer: development and validation of a CT-based model to predict peritoneal metastasis vol.61, pp.6, 2014, https://doi.org/10.1177/0284185119882662
  93. Comparison of surgical outcomes between integrated robotic and conventional laparoscopic surgery for distal gastrectomy: a propensity score matching analysis vol.10, pp.None, 2020, https://doi.org/10.1038/s41598-020-57413-z
  94. Characteristics of metachronous gastric neoplasms after curative endoscopic submucosal dissection for early gastric neoplasms vol.134, pp.21, 2014, https://doi.org/10.1097/cm9.0000000000001762
  95. Establishing Machine Learning Models to Predict Curative Resection in Early Gastric Cancer with Undifferentiated Histology: Development and Usability Study vol.23, pp.4, 2021, https://doi.org/10.2196/25053
  96. Clinicopathological features and lymph node metastasis risk in early gastric cancer with WHO criteria in China: 304 cases analysis vol.50, pp.None, 2014, https://doi.org/10.1016/j.anndiagpath.2020.151652
  97. Targeting Lactate Dehydrogenase A with Catechin Resensitizes SNU620/5FU Gastric Cancer Cells to 5-Fluorouracil vol.22, pp.10, 2014, https://doi.org/10.3390/ijms22105406
  98. Sp1-Induced FNBP1 Drives Rigorous 3D Cell Motility in EMT-Type Gastric Cancer Cells vol.22, pp.13, 2014, https://doi.org/10.3390/ijms22136784
  99. Incidence and treatment outcomes of leakage after gastrectomy for gastric cancer: Experience of 14,075 patients from a large volume centre vol.47, pp.9, 2014, https://doi.org/10.1016/j.ejso.2021.02.013
  100. Long-term Outcomes of Undifferentiated-Type Early Gastric Cancer with Positive Horizontal Margins after Endoscopic Resection vol.15, pp.5, 2021, https://doi.org/10.5009/gnl20291
  101. Pleiotropic nature of curcumin in targeting multiple apoptotic‐mediated factors and related strategies to treat gastric cancer: A review vol.35, pp.10, 2014, https://doi.org/10.1002/ptr.7158
  102. Detection of sarcopenic obesity and prediction of long‐term survival in patients with gastric cancer using preoperative computed tomography and machine learning vol.124, pp.8, 2014, https://doi.org/10.1002/jso.26668
  103. Machine learning predicts lymph node metastasis of poorly differentiated-type intramucosal gastric cancer vol.11, pp.1, 2014, https://doi.org/10.1038/s41598-020-80582-w
  104. Effect of non-curative endoscopic submucosal dissection on short-term outcomes of subsequent surgery for early gastric cancer vol.45, pp.1, 2022, https://doi.org/10.1016/j.asjsur.2021.05.008